Drug Profile
AAT 076
Alternative Names: AAT-076; RMX 1001; RQ-00317076Latest Information Update: 17 Jul 2023
Price :
$50
*
At a glance
- Originator RaQualia Pharma
- Developer AskAt; HaiHe Biopharma; RaQualia Pharma
- Class Analgesics; Small molecules
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute pain
- Phase I Neuropathic pain
- No development reported Postoperative pain
Most Recent Events
- 14 Jul 2023 RaQualia Pharma is still in phase I trials for Neuropathic pain (unspecified) in (China) (RaQualia Pharma pipeline, July 2023)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Neuropathic-pain in China
- 03 Mar 2021 AAT 076 is available for licensing as of 03 Mar 2021. https://askat-inc.com/